Pyrimethamine is a medication used for protozoan infections. It is
commonly used as an antimalarial drug (for both treatment and
prevention of malaria), and to treat Toxoplasma gondii infections,
particularly when combined with the sulfonamide antibiotic
sulfadiazine when treating HIV-positive individuals. Pyrimethamine is
typically given with a sulfonamide and folinic acid due to its
resistance against many Plasmodium species. Pyrimethamine has also
been found to limit the expression of the superoxide dismutase 1
gene, a protein involved in amyotrophic lateral sclerosis.
Pyrimethamine is considered in the list of one of the most important
medications by World Health Organization’s list of essential
medicines. Pyrimethamine’s ability to cure protozoan infection and
toxoplasma infections, rising number of HIV positive patients
worldwide and immunosuppressed individual at a risk of infections are
the factors driving the pyrimethamine treatment market during the
forecast period. Moreover, mergers and acquisitions by the
manufacturing companies would also the boost the demand and supply
for the pyrimethamine medication in the pyrimethamine treatment
market.
However, the certain side effects that may occur with pyrimethamine
medication include allergic reactions, blood disorders, tongue
changes, blood in the urine, heart rhythm disorders, anorexia, and
vomiting (see Important Safety Information below) which act as a
restraining factor for the growth of this market. Additionally,
factors such as pricing issues in some countries and resistance
developing against the drugs may hamper the growth of the
pyrimethamine treatment market during the focus period of 2013 to
2023.
The global pyrimethamine market has been segmented into brands and
geography. On the basis of brand, the pyrimethamine treatment market
has been segmented into two drugs that are presently marketed such as
Daraprim and Fansidar. The Daraprim sub-segment held the largest
share for the pyrimethamine treatment market. However, the Fansidar
sub-segment is growing at a high rate due to affordable cost and
availability.
Download Report Brochure @
https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=8170
Geographically, North America dominates the global pyrimethamine
treatment market followed by Europe. The market domination was
majorly due to the pricing structure of the pyrimethamine drug in the
U.S. The High prevalence of toxoplasma in the region also acts as the
driving factor for the growth of the pyrimethamine treatment in the
North America. According to The Centers for Disease Control and
Prevention (CDC), toxoplasmosis is one of the five neglected
parasitic infections in the U.S.
It is the second leading cause of death from foodborne illness in the
country and more than 60 million people in the U.S. carry the
toxoplasma parasite, and more than one million people in the U.S. are
infected annually with the toxoplasma parasite, which is associated
with high rates of morbidity and mortality. Asia-Pacific is also
increasing constantly in the pyrimethamine drugs market mainly due to
the high prevalence of protozoan disease such as malaria in India,
China and other developing nations. Moreover, government initiatives
and regulatory norms in these countries would fuel the market for
pyrimethamine treatment market in the region during the forecast
period. Latin America is also a growing market for pyrimethamine
treatment due to developing healthcare expenditure and high
prevalence rate of malaria and toxoplasma in the region.
Some of the major players in pyrimethamine treatment market include
Turing Pharmaceuticals, Impax Laboratories, Inc., Pfizer, Inc.
GlaxoSmithKline plc, and others.
Pre-Book Full Report @
https://www.transparencymarketresearch.com/checkout.php?rep_id=8170<ype=S
About Us
Transparency Market Research (TMR) is a market intelligence company,
providing global business information reports and services. Our
exclusive blend of quantitative forecasting and trends analysis
provides forward-looking insight for thousands of decision makers.
TMR’s experienced team of analysts, researchers, and consultants,
use proprietary data sources and various tools and techniques to
gather, and analyze information. Our business offerings represent the
latest and the most reliable information indispensable for businesses
to sustain a competitive edge.
Each TMR syndicated research report covers a different sector - such
as pharmaceuticals, chemicals, energy, food & beverages,
semiconductors, med-devices, consumer goods and technology. These
reports provide in-depth analysis and deep segmentation to possible
micro levels. With wider scope and stratified research methodology,
TMR’s syndicated reports strive to provide clients to serve their
overall research requirement.
US Office Contact
90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email:
sales@transparencymarketresearch.com
Website:
https://www.transparencymarketresearch.com
No comments:
Post a Comment